Peer-reviewed veterinary case report
Blood test detects autoantibodies to predict dog mammary tumors
By Wu, Chih-Ching et al.·Published in The veterinary quarterly·2025·Graduate Institute of Biomedical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors.
- Species:
- dog
Plain-English summary
A study found that dogs with mammary tumors had higher levels of certain autoantibodies in their blood compared to healthy dogs. This means that measuring these autoantibodies could help vets detect mammary tumors earlier and predict how well a dog might do after treatment. The test showed about 50% sensitivity, meaning it could identify half of the dogs with tumors, and 90% specificity, indicating it was good at confirming healthy dogs. Higher levels of these autoantibodies were linked to worse survival rates, suggesting they could be useful for monitoring the disease's progression.
People also search for: dog mammary tumor symptoms · early detection of canine mammary tumors · autoantibodies in dogs
Abstract
Canine mammary tumor (CMT) is a prevalent and destructive disease often diagnosed at an advanced stage, leading to poor outcomes. Currently, there is a lack of effective biomarkers for early detection and prognostic prediction of CMT. To improve CMT detection, we established a multiplexed immunoassay using a fluorescence bead-based suspension array system to measure serum levels of autoantibodies against four CMT-associated proteins (AGR2, HAPLN1, IGFBP5, and TYMS) in CMT patients. Our data revealed that serum levels of the four autoantibodies (anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS) were significantly elevated in CMT patients ( = 158) compared to healthy individuals ( = 39). Notably, serum levels of anti-AGR2, anti-HAPLN1, and anti-TYMS in the dogs with stage I CMT ( = 56) were higher than those in the healthy group. Using a marker panel consisting of the four autoantibodies for detecting malignant CMT ( = 125) achieved a sensitivity of 50.4% and a specificity of 90%. Furthermore, higher levels of anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS were associated with poorer survival in CMT patients. Collectively, we established a multiplexed immunoassay platform to detect serum autoantibodies and demonstrated that a tailored autoantibody marker panel shows potential clinical applicability for the diagnosis and prognosis of CMT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39639821/